Grants for Independent school districts - Health

This funding opportunity supports the development of innovative molecular and genetic tools for neuroscientific research, enabling precise access to specific brain cell types across various vertebrate species, with a strong emphasis on collaboration, inclusivity, and resource sharing.

This funding opportunity supports doctoral students from underrepresented backgrounds in mental health research to complete their dissertation projects and advance their careers in the field.

This funding opportunity supports research projects that aim to improve access to and effectiveness of treatment for Alcohol Use Disorder, particularly for underserved populations, by addressing barriers and enhancing care delivery.

This funding opportunity supports researchers who have received a specific career development award to conduct small-scale projects that will help them become independent investigators.

The NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional), designated as PAR-22-241, is a funding opportunity issued by the NIH's National Institute of Allergy and Infectious Diseases (NIAID). The program targets New Investigators (NI) and At-Risk Investigators from underrepresented backgrounds in the biomedical, clinical, behavioral, and social sciences. New Investigators are those who have not previously secured substantial independent NIH funding, while At-Risk Investigators are those with previous funding but face a lack of funding in the following fiscal year unless a new grant is awarded. This initiative aligns with the goals of the 21st Century Cures Act to encourage new researchers, foster early independence, and support a more diverse scientific workforce. This funding announcement supports research relevant to the NIAID mission, including the study and treatment of infectious, immunologic, and allergic diseases. Research areas of focus include microbiology, immunology, infectious diseases, AIDS, transplantation, and emerging diseases. Although clinical trials are optional, applicants proposing NIH-defined clinical trials must consult with NIAID before submission. The funding opportunity is open to projects that advance diversity in the R01 investigator pool and those promoting representation from underrepresented groups in line with NIH’s interest in enhancing diversity across all health-related fields. To apply, investigators must be affiliated with U.S.-based higher education institutions or eligible nonprofits and for-profit organizations. This opportunity is also open to minority-serving institutions, such as Hispanic-serving Institutions, HBCUs, and Tribally Controlled Colleges and Universities. Non-domestic (non-U.S.) entities are not eligible, although foreign components of U.S. organizations are permitted. An essential part of the application process is an Eligibility Certification Letter from the applicant institution verifying the applicant’s eligibility and alignment with the program’s diversity objectives. Applications missing this letter will be considered incomplete. Funding levels are based on the project’s actual needs and are not capped, with a project duration of up to five years. NIAID also expects applicants to allocate funding in their budgets for mandatory attendance at a workshop designed to foster networking, collaboration, and professional growth among awardees, to be held every three years starting in 2025. Additional support for necessary accommodations for researchers with disabilities may also be included in the budget. The application process requires thorough adherence to NIH’s submission guidelines, which include registrations with SAM, Grants.gov, eRA Commons, and the acquisition of a UEI. Applications are accepted electronically through the NIH ASSIST system, Grants.gov Workspace, or a system-to-system solution. The next deadline cycle follows NIH’s standard due dates, with submissions due at 5:00 PM local time. Applicants are advised to submit early to address potential errors before the due date. Applications will be evaluated on scientific merit and alignment with program priorities, using criteria focused on the significance of the research, investigator qualifications, project innovation, approach, and institutional environment. Specific review criteria for clinical trials include the adequacy of study design, data management, and statistical analysis plans. Following peer review, recommended applications will receive secondary review by the NIAID advisory council. Final award decisions consider both scientific merit and relevance to NIAID’s mission and diversity goals.

This funding opportunity supports researchers in developing innovative theories and methods to better understand the complex genetic and non-genetic factors influencing human traits and health, with a focus on interdisciplinary approaches and diverse perspectives.

This funding opportunity provides support for mid-career and senior researchers to gain new skills and knowledge in dental, oral, and craniofacial research by collaborating with experts in different scientific fields.

This funding opportunity provides financial support to a wide range of organizations for improving public health surveillance and treatment practices for inherited bleeding disorders, ultimately aiming to enhance health outcomes for affected individuals.

This funding opportunity supports U.S. institutions and organizations in developing centers that integrate advanced translational science into cancer clinical trials, enhancing research on precision medicine and rare cancers.

This funding opportunity provides support for research projects that utilize health information technology to improve healthcare access, quality, and outcomes for underserved populations in the U.S. experiencing health disparities.

The grant titled "BRAIN Initiative: Engineering and optimization of molecular technologies for functional dissection of neural circuits" aims to support the development and enhancement of molecular tools that can specifically target brain cells, enabling the observation and control of neural circuits in experimental animals.

This funding opportunity supports researchers conducting early phase clinical trials on natural products, such as botanicals and dietary supplements, to evaluate their effects on health and inform future studies.

This funding opportunity provides financial support for researchers to develop innovative screening methods and therapies for newborn conditions, aiming to improve early detection and management of potentially serious health issues in infants.

The purpose of the NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support of a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIHs Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

This(NOFO) aims to innovate, implement, and evaluate approaches to One Health laboratory diagnostic network optimization and specimen transport in Liberia. This multi-component NOFO is designed to address the inter-dependence of a comprehensive, resource-mapped, accredited national and sub-national laboratory network, the physical transportation architecture required to transfer network commodities (namely human, animal, and environmental specimens) point-to-point, and the optimization of digital communication, information, and supply chain systems necessary to sustain the network itself.

This Notice of Funding Opportunity (NOFO) invites applications from institutions/organizations that propose to establish a Research Resource Center (RRC) for the NIDDK Nutrition Obesity Research Centers (NORC) Program. The NORC Program consists of eleven Centers across the nation that support and enhance the national research effort in nutrition and obesity through cutting-edge basic, clinical, translational, and health disparities research in nutrition science and obesity. In collaboration with the existing NORC program, the RRC will (1) provide administrative support for the entire NORC Program, (2) establish and curate a NORC Program website and centralized repository of research resources , (3) implement a multipronged approach to support and grow the early-to-midcareer research workforce, including individuals from diverse backgrounds, with a goal of maximizing national outreach and impact, (4) administer and manage a NORC Opportunity Program to address gaps and promote collaboration, and (5) manage a Pilot and Feasibility Program.This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Funding Opportunity Description Developing medical countermeasures to protect civilians against intentional and accidental toxic chemical exposure that can lead to mass casualties is a major goal of the biodefense program at NIH. More specifically, this goal is executed by the Chemical Countermeasures Research Program (CCRP) at NIAID in partnership with several other ICs across the NIH (NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats). NIAMS has been a critical and active partner in this trans-NIH effort since the CCRP’s inception in 2006. In order to broaden its research base and raise the awareness of the scientific community at large about the urgent need for effective countermeasures against chemical threats, the CCRP is encouraging its IC partners to issue IC-specific FOAs to further engage their respective research disciplines that are not currently engaged in the medical countermeasure research field. This initiative is a response to that request. The intent of the initiative is to encourage the NIAMS skin research community to contribute to the basic understanding of injuries caused by those toxic chemicals identified by the U.S. Department of Homeland Security as high consequence public health threats and to explore the local and systemic mechanisms of chemical wound development, healing, and long-term consequences. It is envisaged that such initiative will benefit both the national civilian defense program as well as the basic skin wound healing research at large. This initiative will emphasize understanding commonalities in the fundamental mechanisms of skin injuries caused by vesicants such as sulfur mustard, Lewisite, nitrogen mustard, phosgene oxime, and arsenicals, which may be different from thermal burn. The investigators are also encouraged to collaborate with researchers in tissues other than skin that are affected by the vesicants (e.g., eyes and lung) to find commonalities of injury mechanisms shared with skin. It is hoped that the fundamental knowledge gained would ultimately lead to the discovery and characterization of potential shared therapeutic targets (e.g., in signal transduction pathways and inflammation process) and the development of broad-spectrum medical countermeasures. This FOA is intended for investigators who are not currently supported under the CCRP’s CounterACT program but whose research interests are relevant to skin chemical injuries and to skin wound healing in general. It is assumed that the proposed project will represent a new direction for the applicant, which requires the applicant’s research lab to acquire new skills (e.g., handling toxic chemicals), gather new resources (e.g., establishing collaborative or contractual relationships with facilities certified to utilize restricted/controlled chemicals) and generate new preliminary data. Therefore, this FOA uses a planning mechanism (R34) to support such investigators to commence the preparatory steps toward this new line of study. This means that the applicants do not need to present preliminary data supporting the proposed study in concept, nor publication records and specific skills and proficiency in experimental execution in the chemical medical countermeasures field. However, the PD/PI should demonstrate prior experience in wound healing research and general knowledge relating to skin injury and healing. It is expected that a successful outcome of a proposed project is that the investigator has added within the laboratory (if needed) personnel with the skills and expertise to conduct studies in this area, established a working relationship with facilities certified for toxic chemicals (if needed), and gathered sufficient preliminary data to support a more comprehensive research project suitable under the other more translationally-focused CCRP FOAs.

This funding opportunity supports research projects that explore innovative combinations of radiation therapy and other treatments to improve cancer care, inviting applications from a diverse range of organizations, including universities, nonprofits, and for-profit entities.

This funding opportunity supports small-scale research projects that aim to improve the use of genomic information in clinical care, particularly for diverse and historically underrepresented populations.

The "Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)" grant is a $2.5 million funding opportunity from the CDC and ATSDR, aimed at supporting research to better understand potential risk factors for ALS, with a focus on environmental and occupational exposures, military service, traumatic brain injury, neuroinflammation, contact sports, and infectious agents, especially in underrepresented populations.